Science

Researcher interest in CBD has been growing over the last two decades and has accelerated in the last five years. The sector now has an encouraging volume of research and publications for an array of maladies it can help.

Total Proportion of Medical Cannabis Publication By Target

Total Proportion of Medical Cannabis Publication By Target

Clinical Trials

Research and understanding around CBD is growing as a result of extensive clinical trials taking place across a number of countries. More than 275 clinic trails including trials running across multiple countries.

There is evidence supporting cannabinoid efficacy in a number of therapeutic areas especially in pain management, cancer, mood disorders and spasticity.

Brains Involvement In Clinical Trials

As one of the world’s few registered GMP-grade natural CBD API’s, Brains Bio’s CBD API is in increasing demand and is currently being utilised in 15 clinical trials around the world, exploring the effects of CBD on treating epilepsy, psychosis, anxiety & depression and PTSD.

Manufacturing

  • Prati Donaduzzi | Brazil Phase III Clinical Trial with our CBD API
    • Epilepsy

Scientific Partners

  • King’s College London | UK
  • Trigal Pharma | Austria COVID-19

Researchers & Academics

  • University of Sao Paulo | Brazil
    • Anxiety

Pre-Clinical Trials

As one of the world’s few registered GMP-grade natural CBD API’s, Brains’ CBD API is incr

Power of Cannabinoids

How CBD API Works

Endocannabinoid System

The endocannabinoid system (ECS) has been implicated as an emerging target of therapeutic potential for a wide range of diseases.

Brains is the exclusive supplier of pharmaceutical-grade natural CBD API to Prati Donaduzzi, for their Phase III clinical trial on refractory epilepsy.